1. Home
  2. SLNH vs CRDL Comparison

SLNH vs CRDL Comparison

Compare SLNH & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

BUY

Current Price

$0.59

Market Cap

271.5M

Sector

Technology

ML Signal

BUY

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

BUY

Current Price

$1.10

Market Cap

226.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
SLNH
CRDL
Founded
1961
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.5M
226.6M
IPO Year
2005
2017

Fundamental Metrics

Financial Performance
Metric
SLNH
CRDL
Price
$0.59
$1.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$4.00
★ $8.49
AVG Volume (30 Days)
★ 7.0M
1.5M
Earning Date
11-16-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 80.41
N/A
EPS
N/A
★ N/A
Revenue
★ $38,021,000.00
N/A
Revenue This Year
$107.79
N/A
Revenue Next Year
$0.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 80.49
N/A
52 Week Low
$0.59
$0.88
52 Week High
$4.04
$2.34

Technical Indicators

Market Signals
Indicator
SLNH
CRDL
Relative Strength Index (RSI) 17.31 20.62
Support Level $0.59 $0.96
Resistance Level $0.82 $1.10
Average True Range (ATR) 0.07 0.08
MACD -0.04 -0.03
Stochastic Oscillator 1.23 1.59

Price Performance

Historical Comparison
SLNH
CRDL

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: